The Potential of Gene Therapy in Ophthalmic Disorders
The eyes are considered one of the first parts of the body to deteriorate, and this area directly affects the quality of life for both humans and animals.
With this partnership announced three days ago, Astellas will initially pay approximately 2.8 billion yen to 4D Molecular Therapeutics (4DMT). There is also the possibility of additional payments based on development progress, potentially totalling up to around 132.7 billion yen in addition to revenue-based compensation. This can be considered one of the significant licensing deals in the fiscal year 2023.
4DMT is a company that has administered a clinical program using the R100 technology to more than 70 patients suffering from exudative age-related macular degeneration and rare ophthalmic diseases. Astellas will now have access to the “R100” AAV owned by this company. (R100 is known for its ability to efficiently deliver therapeutic genes to retinal cells.)
When discussing cell and gene therapy, we often think of disease areas related to cancer like CAR-T. However, research and development are also advancing in the field of ophthalmology in countries such as the United States, Europe, and China. We anticipate further growth in this space.
For those interested in team building and advisory roles related to CGT, regenerative medicine, and related products, both domestically and internationally, including development directors, regulatory affairs directors, or manufacturing/quality assurance directors, please don’t hesitate to reach out to our GS Life Sciences team.